natgillin/translations-raw huggingface dataset:
it comprises no detectable terminal Gal alpha 1-3Gal; and/or it comprises an amount of fucose on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% less compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
(v) ne sadrži opazivi terminal Gal(a1,3)Gal; i/ili (vi) sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod navedenih molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 5% manja u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
the second binding domain is capable of binding to CD3; and wherein epitope cluster 3 of BCMA corresponds to amino acid residues 24 to 41 of the sequence as depicted in SEQ ID NO: 1002, and wherein said binding molecule is a polypeptide. 
(b) druga vezujuća domena sposobna je za vezanje na CD3; i pri čemu epitop klastera 3 od BCMA odgovara ostatcima aminokiseline 24 do 41 od sekvence kao što je prikazano u SEQ ID NO: 1002, i pri čemu je navedena vezujuća molekula polipeptid.
The process according to the previous claim, wherein the adsorption of said CO2 is effected on said second treatment unit (U2) while the solid sorbent (25) of said first treatment unit (U1) is subjected to regeneration. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što se adsorbiranje navedenog CO, provodi u navedenoj drugoj jedinici za obradu (U2) dok se čvrsti sorbent (25) navedene prve jedinice za obradu (Ul) podvrgava regeneriranju.
In an embodiment, the immunogenic composition of the invention comprises at least two further bacterial saccharides conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna bakterijska saharida su konjugirani s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRM197, C fragment proteina TT, protein D, OMPC i pneumolizin.
in which at least 6 burners (21) are arranged on the burner circle line, preferably 6 to 10 burners, more preferably 6 to 8 burners. 
10.16 gdje se najmanje 6 plamenika (21) nalazi na liniji plameničkog kruga, po mogućnosti 6 do 10 plamenika, poželjnije 6 do 8 plamenika.
Balance (Mettler Toledo or equvalent). Materials 
- - Vaga (Mettler Toledo ili njen ekvivalent).
The method of claim 1, wherein the antibody or antigen binding fragment thereof further comprises a human IgG4 constant region, and a human k light chain constant region. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od zahtjeva 1-3, naznačen time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži human IgG4 konstantnu regiju, i humanu K konstantnu regiju lakog lanca.
a cholestanol derivative represented by formula (1): (wherein G is GlcNAc-Gal- or GlcNAc-) or a cyclodextrin inclusion compound thereof, and 
LAI 2 (pri čemu G predstavlja GIeNAc- ili GleNAc-Gal-) ili njihov inkluzijski spoj ciklodekstrina, i irimotekan kao protutumorsko sredstvo.
An aqueous pharmaceutical composition formulated for parenteral administration comprising a complex comprising allopregnanolone and sulfobutyl ether B-cyclodextrin, wherein the allopregnanolone is at a concentration of 5 mg/ml and the sulfobutyl ether B-cyclodextrin is at a concentration between 25-400 mg/mL, wherein the formulation is buffered to a pH of 6 and the buffer is a citrate buffer. 
Vodena farmaceutska kompozicija formulirana za parenteralnu primjenu, naznačena time, što uključuje kompleks koji sadrži alopregnanolon i sulfobutil eter B-ciklodekstrin, gdje je alopregnanolon prisutan u koncentraciji od 5 mg/ml i sulfobutil eter B-ciklodekstrin je prisutan u koncentraciji između 25-400 mg/mL, pri čemu je formulacija puferirana na pH 6 i pufer je citratni pufer.
flowing the resulting treated hydrocarbon-containing fluid through said pipeline, wherein said first particles have a mean particle size in the range of from 25 to 1,500 micrometers, wherein said second particles have a mean particle size of less than 10 micrometers, wherein said first and second particles are introduced into said hydrocarbon-containing fluid either jointly or separately, 
protjecanje rezultirajućeg tretiranog fluida koji sadrži ugljikovodik kroz navedeni cjevovod, gdje je najmanje dio navedenih drugih čestica formiran putem emulzijske polimerizacije, gdje navedene prve i druge čestice su uvedene u navedeni fluid koji sadrži ugljikovodik bilo zajedno bilo odvojeno;
A compound for use according to claim 7, wherein the disorder or disease is characterized by an abnormal activity of aldosterone synthase. A compound for use according to claim 7, wherein the disorder or the disease is selected from hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction. 
Spoj za uporabu prema zahtjevu 7, naznačen time, da je poremećaj ili bolest karakteriziran(a) s nenormalnim djelovanjem sinteze aldosterona, Spoj za uporabu prema zahtjevu 7, naznačen time, da je poremećaj ili bolest odabran(a) od sljedećih: hipokalijemija, hipertenzija, kongestivni srčani zastoj, atrijska fibrilacija, zastoj bubrega, posebno kronični zastoj bubrega, restenoza, ateroskleroza, X-sindrom, pretilost, nefropatija, post-miokardijski infarkt, koronarne srčane bolesti, zapaljenje, povećana tvorba kolagena, fibroze kao što su kardijske i miokardijske fibroze te remodeliranja koja prate hipertenziju i endotelijalnu disfunkciju.
The amount of high intensity sweetener of this partial sugar replacement composition should be adapted in order to obtain a sweetness of about equal the sweetness of sucrose. 
Količinu sladila velike slatkoće u toj sastavini koja djelomice zamjenjuje šećer treba prilagoditi tako, da se dobije slatkoća približno jednaka slatkoći saharoze.
an ending point of the coating process forming the coating of the solid dosage form is controlled in accordance with the monitored property of the coating; 
krajnja točka postupka oblaganja koja tvori prevlaku čvrstog oblika doziranja kontrolira se u skladu s nadziranim svojstvom prevlake;
The controlled release composition according to embodiment 30 for administration once daily. 
Sastav za kontrolirano otpuštanje u skladu s patentnim zahtjevom 1 za primjenu jednom dnevno.
mixing nicotine or a pharmaceutically acceptable nicotine salt or complex with an excipient; 
(a) miješanja nikotina ili farmaceutski prihvatljive nikotinske soli ili kompleksa s pomoćnom tvari;
A surprising - and so far fully unknown - property of dimethyl polysiloxane is that in the course of pelletization, when emulged in an amount of not exceeding 5% by weight into water or an aqueous colloidal solution of xanthane gum used for the pelletization, it improves the spherical shape of the pellets and augments the ratio of the product fraction. 
Iznenađujuće se - i dosad posve nepoznato - jedno svojstvo dimetil polisiloksana je da tijekom granuliranja, kada se emulgiran u količini koja ne prelazi 5% (težinski) u vodi ili vodenoj koloidnoj otopini ksantanske gume koristi za granuliranje, poboljšava kuglasti oblik granula i povećava udio frakcije produkta.
The chromosome aberration assay was conducted using standard procedures2-6 by exposing cultures of CHO cells to a minimum of four concentrations of the test article as well as to the positive and vehicle controls. 
Test kromosomskih aberacija je izveden primjenom standardnih postupaka"" izlaganjem kultura CHO stanica minimumu od četiri koncentracije test spoja kao i pozitivnoj kontroli i kontroli sa nosačem.
The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. 
Spoj se može sterilizirati izlaganjem etilen-oksidu prije suspendiranja u sterilnom vehikulumu.
Foam slate during mixing of the first and second agents (in the container) 
(33) Država ili organizacija podnošenja prve prijave: JP
The antibody or antigen binding portion according to claim claim 1 or claim 5, comprising the VH polypeptide amino acid sequence as set forth as SEQ ID NO:70 and the VL polypeptide amino acid sequence as set forth as SEQ ID NO:81. 
Protutijelo ili njegov dio koji veže antigen prema bilo kojem od zahtjeva 1-15, naznačeno time da sadrži sekvencu amino kiseline lakog lanca pune duljine koja ima barem 95 posto identičnosti sekvence sa SEQ ID NO: 1251 sekvencu amino kiseline teškog lanca pune duljine koja ima barem 95 posto identičnosti sekvence sa SEQ ID NO: 17.
x and y can be both a single bond; when x is a double bond, then y is a single bond and R4 and R16 are absent; when y is a double bond, then x is a single bond and R5 and R16 are absent; 
x i y oba mogu biti jednoguba veza; kada je x dvoguba veza, tada je y jednoguba veza i R4 i R16 su odsutni; kada je y dvoguba veza, tada je x jednoguba veza i R5 i R16 su odsutni;
Authentication method according to claim 2 or 3, wherein each of said text messages corresponds to only one SMS or MMS. 
Postupak autentifikacije sukladno Zahtjevu 2 1li 3, pri čemu svaka od navedenih tekstualnih poruka odgovara samo jednoj SMS (kratka tekstualna poruka) i/ii MMS (multimedijalna poruka) poruci.
“C3-C15-carbocyclic group”, as used herein, denotes a carbocyclic group having 3- to 15-ring carbon atoms, e.g., a monocyclic group, either cycloaliphatic, such as a C3-C8-cycloalkyl, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; or aromatic, such as phenyl; or a bicyclic group, such as bicyclooctyl, bicyclononyl including indanyl and indenyl, and bicyclodecyl including naphthyl. 
"C3-Cis-karboksilna skupina", kako se ovdje rabi, označava karbocikličku skupinu koji ima 3 do 15 ugljikovih atoma u prstenu, npr. monociklička skupina, cikloalifatska, kao što je C,-Cg-cikloalkil, npr., ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil ili ciklooktil; ili aromatska, kao što je femil; ili biciklička skupina, kao što je biciklooktil, biciklononil uključivo indanil i indenil, i biciklodecil uključivo naftil.
Modular antibody according to claim 1, which has a binding affinity of Kd<10-8 M. Modular antibody according to claims 1 or 2, which has at least one of ADCC, ADCP and CDC activity. 
Modularno antitijelo prema patentnom zahtjevu 1, koje ima najmanje jedno od – stanično posredovana citotoksičnost zavisna od antitijela (ADCC), stanična fagocitoza zavisna od antitijela (ADCP), citotoksičnost zavisna od komplementa (CDC) ili apoptotična aktivnost. Modularno antitijelo prema patentnom zahtjevu 2, koje ima apoptotičnu aktivnost.
Floor panel according to any of the claims 1 to 6, characterized in that the locking element (12) is formed by coextrusion. 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što sadrži dio na pritisak (15) koji lateralno djeluje na tijelo za zaključavanje (14).
The circuit according to claim 6, in which the second frequency control means comprises: 
Raspored prema zahtjevu 5 ili 6, naznačen time, da drugi upravljački sklop za frekvenciju (42) sadrži:
This technique has its limitations as coating of fine particles is usually technology intensive and coated granules are readily ruptured by chewing and compression. 
Ta tehnika ima ograničenja utoliko što je oblaganje finih čestica obično tehnološki intenzivno i obložene granule redovito pucaju žvakanjem i komprimiranjem.
in reaction (P-reac) the compound of formula (XXIV) is exposed to a temperature (P-temp); 
Kod reakcije (P-reak.) spoj (XXIV) bude podvrgnut temperaturi (P-temp.);
The veterinary or agricultural composition according to claims 1-17, wherein the additional active agent is an insect growth regulator. 
Veterinarski ili agrikulturni sastav prema zahtjevima od 1 do 17, naznačen time, da dodatna djelatna tvar je regulator rasta kukaca.
The device of any of claims 1 to 10, wherein the proximal end of the tip member is convex shaped relative to the proximal portion of the tip member. 
Element fototerapijskog uređaja u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je bliski kraj vršnog elementa fleksibilnog optičkog vlakna konveksnog oblika u odnosu na bliski dio vršnog elementa fleksibilnog optičkog vlakna.
An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment according to any one of the preceding claims. A vector comprising the nucleic acid molecule of claim 7. 
Izolirana molekula nukleinske kiseline, naznačen time, da kodira protutijelo ili fragment koji veže antigen u skladu s patentnim zahtjevom 1 ili 2.
A product comprising the dry glassy stabilizing composition of claim 1, wherein the product is a food, a food additive, an animal feed, an animal feed additive, or a nutraceutical, pharmaceutical or vaccine product. 
Proizvod za oralnu potrošnju koji sadrži suhu stabilizirajuću kompoziciju za stabiliziranje sukladno patentnom zahtjevu 1. Postupak pripreme sukladno patentnom zahtjevu 11, naznačen time da je taj proizvod nutraceutski, farmaceutski proizvod ili proizvod cjepiva.
A genic expression adenoviral hybrid vector according to claim 1, characterized in that element iii is a tumor specific promoter having the sequence SEQ ID NO: 7, corresponding to AFP p+e. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema patentnom zahtjevu 1, naznačen time što je element iii. tumor specifični promotor koji ima sekvencu izabranu od SEQ ID Neo 7, koja odgovara AFP p+e, i SEQ ID No 15, koja odgovara telomeraza TERT.
For example, 10% or 6% of the combined weight of honey and L-alanyl-L-glutamine of the combined product may be L-alanyl-L-glutamine, or less. 
Kombinirani proizvod za primjenu u skladu sa zahtjevom 6, naznačen time što 10 % ili manje ukupne težine meda i L-alanil-L-glutamina, čini L-alanil-L-glutamin.
Lipoprotein oxidation induced in vitro in plasma is expected to represent a relevant model of the lipoprotein oxidation in the arterial wall. 
Očekuje se da oksidacija lipoproteina izazvana in vitro u plazmi predstavlja relevantan model oksidacije lipoproteina u arterijskoj stijenci.
determining a paternal allele inherited by the fetus from the father at each of a first plurality of loci, the identified locations of the nucleic acids of the biological sample determined in (a)(i) including the first plurality of loci, wherein the first plurality of loci are on a same chromosome, wherein the maternal genome is heterozygous at the first plurality of loci; 
određivanju, računalnim sustavom, drugog udjela lokusa iz prve skupine lokusa u kojoj je odgovarajući prvi alel detektiran iz rezultata sekvenciranja; i na osnovi drugog udjela, određivanju prvog udjela fetusnog genoma sekvenciranog iz biološkog uzorka.
The oral pharmaceutical composition according to claim 1 wherein the compound of Formula (I) is selected from the group consisting of: 
Spoj bilo kojeg od patentnih zahtjeva 1 do 5, odabrano od grupe koja se sastoji od:
wherein (B) the step of storing the polypropiolactone occurs at the second location. 
(B) korak skladištenja polipropiolaktona se provodi na drugoj lokaciji.
17 and the three light chain CDRs of sequence SEQ ID No. 
17 te tri laka lanca CDRs sekvencije SEQ ID br.
b is 0 or an integer from 1 to 3; each R6 is independently selected from halo, -OH, -CH3, -OCH3, -CN, and -CF3; where each alkyl group in R1 and R4 is optionally substituted with 1 to 8 fluoro atoms; and where the methylene linker on the biphenyl is optionally substituted with one or two -C1-6alkyl groups or cyclopropyl; 
b je 0 ili cijeli broj od 1 do 3; svaki R6je neovisno odabran od halo, -OH, -CH3, -OCH3, -CN, i-CF3; pri čemu je svaka alkilna skupina u R1 i R4 po izboru supstituirana s 1 do 8 atoma fluora; i pri čemu je metilenski linker na bifenilu po izboru supstituiran s jednom ili dvije -C1-6alkilne skupine ili s ciklopropilom;
Particularly preferred drugs for delivery using lozenges of the invention include nicotine, the analgesic A9-THC, the anti-emetic ondansetron (a 5-HT3 antagonist), and the anti-migraine drug sumatriptan (a 5-HT1 agonist). 
Posebno poželjni lijekovi za primjenu uporatrebom tableta prema izumu obuhvaćaju nikotin, analgetik A9-THC, antiemetik ondansetron (5-HT3 antagonist), i lijek protiv migrene sumatriptan (5-HT, agonist).
Sintering said powder to form an agglomerated cake and texturising the agglomerated cake to obtain an instant beverage powder, wherein the porous base powder is characterised in that it has a particle porosity of at least 45%, wherein the pores have a D50 diameter of less than 80 micrometres and has a pore diameter distribution span of less than 4. 
Postupak proizvodnje instant napitka u prahu koji se sastoji u koracima: a. < osiguravanja poroznog partikuliranog osnovnog praha; b. sinteriranja navedenog praha kako bi se dobilo aglomerirani kolač; 1 c. teksturiranja aglomeriranog kolača kako bi se dobilo instant napitak u prahu, gdje je porozni osnovni prah naznačen time što ima poroznost čestica od najmanje 45%, pore imaju promjer Ds59 manji od 80 um, a raspon raspodjele promjera pora je manji od 4.
LC/MS data were obtained under the following conditions: 
Podaci za LC/MS dobiveni su u sljedećim uvjetima:
The system of one of claims 72-87 wherein the processing circuitry of at least one instance of said radio network equipment is configured to: 
Sustav u skladu s bilo kojim od patentnih zahtjeva 72-87, naznačen time što je sklopovlje za obradu najmanje jedne instance navedene opreme za radio mrežu konfigurirano za:
Second, alkyl and heterocyclyl groups as defined herein are understood to include substituted alkyl and heterocyclyl groups. 
Druga, alkilne i heterocikličke skupine, kao što je ovdje definirano, podrazumijevaju uključivanje supstituiranih alkilnih i heterocikličkih skupina.
a payment server, which is adapted to bill the amount to be paid to the subscriber on the basis of the billing parameters. 
server (180) za plaćanje, koji je prilagođen da naplati navedeni iznos koji treba platiti navedenom pretplatniku (145) na osnovu navedenih parametara naplate pri čemu sustav obuhvaća sredstva za provođenje metode prema patentnom zahtjevu 1.
The method of claims 1 to 6, wherein lyophilizing said microparticles is in the presence of a cryoprotectant, preferably mannitol. A long acting parenteral pharmaceutical composition obtainable by the method according to any one of claims 1.to 7. A long acting parenteral pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable biodegradable carrier selected from the group consisting of poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA), wherein said pharmaceutical composition is in the form of microparticles prepared by a water-in oil-in water double emulsification process, and wherein said pharmaceutical composition is in a sustained release depot form suitable for a dosing schedule from once weekly to once in every 6 months in a dose ranging from 20 to 750mg glatiramer acetate. 
Parenteralno farmaceutski pripravak s dugotrajnim djelovanjem koji sadrži terapeutski učinkovitu količinu glatiramer acetata i poli (D, L-laktid-ko-glikolid) (PLGA) kao farmaceutski prihvatljivi biorazgradivi nosač, a pripravak se nalazi u obliku sustava sa produženim otpuštanjem prikladnim za raspored doziranja od jednom tjedno do jednom u svakih 6 mjeseci u dozi u rasponu od 20 do 750 mg glatiramer acetata, pri čemu sastav sadrži unutarnju vodenu fazu koja sadrži terapeutski učinkovitu količinu glatiramer acetata, polimerne faze koja se ne miješa s vodom i koja sadrži PLGA i vanjsku vodenu fazu, i gdje je pripravak u obliku mikročestica pripravljenih s vodi, u vodi dvostruke emulzije ulja.
Step (iii): crystallizing 5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole of formula 4 in toluene by heating the solution to 85 °C - 95 °C for a period of 1 hour, followed by cooling the solution to 10 °C - 15 °C for the period of 3 hours; 
[image] Korak (iii): kristalizacija 5-metoksi-3-[(4-metil-1-piperazinil)metil]-1H-indol iz formule 4 u toluenu zagrijavanjem otopine do 85 °C - 95 °C tijekom perioda od 1 sat, poslije čega slijedi hlađenje otopine do 10 °C - 15 °C tijekom perioda od 3 sata;
The method or the mixture according to claim 4, wherein the antibodies are derived from mammals, such as human, mice or rats. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa 1li štakora.
• R1 is selected from a C10-C22-alkenyl with 3-6 methylene interrupted double bonds in Z configuration, and a C10-C22 alkynyl having 1-6 triple bonds; 
Lipidni spoj s formulom (I): [image] naznačen time da • R1 je odabran od C10-C22-alkenila s 3-6 metilenskih prekinutih dvostrukih veza u Z konfiguraciji, i -C22 alkinil koji ima 1-6 trostrukih veza;
D-methadone for use according to claim 4, wherein the psychiatric drug is an antidepressant, an anxiolytic, a CNS stimulant, a neuroleptic, an opioid, nicotine, or another NMDA antagonist. 
D-metadon za uporabu prema zahtjevu 4, naznačen time što psihijatrijski lijek je antidepresiv, anksiolitik, stimulans SŽS, neuroleptik, opioid, nikotin, ili drugi antagonist NMDA.
In the course of the pelletization process venlafaxine hydrochloride is mixed with sodium chloride and/or potassium chloride and microcrystalline cellulose The mixture is homogenized and the thus-obtained powdered premix is moistened with water or with an aqueous solution of the binder(s) and/or other, pharmaceutically acceptable excipients. 
Tijekom postupka granuliranja ventafaksin hidroklorid miješa se s natrijevim kloridom i/ili kalijevim kloridom i mikrokristalnom celulozom. Smjesa se homogenizira i tako dobivena praškasta smjesa navlaži se vodom ili vodenom otopinom veziva i/ili drugim farmaceutski prihvatljivim ekscipijentima.
Or ConjE: Where Ab is an antibody that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 
ConjE: jovratrita, gdje Ab predstavlja protutijelo koje se veže na HER2, pri čemu protutijelo obuhvaća VH-domenu koja ima sekvencu u skladu sa
An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.1 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid. 
Oralni oblik doziranja prema zahtjevu 1, naznačen time što teži oko 75 mg i sadrži: 1) spoj A sa sljedećom strukturom: ili njegovu farmaceutski prihvatljivu sol, hidrat, stereoizomer, tautomer ili njihove racemične smjese, u količini koja osigurava 0,1 mg potentnosti spoja A; 2) farmaceutski prihvatljiv nosač ili pomoćnu tvar, pri čemu je nosač ili pomoćna tvar smjesa škroba i laktoze; i 3) sredstvo za povećanje skliskosti, pri čemu je sredstvo za povećanje skliskosti stearinska kiselina.
For Examples 12-14, in which the drug was sumatriptan succinate, the drug was added as a powder or an aqueous solution. 
Za Primjere 12-14, u kojima je lijek sumatriptan sukcinat, lijek je dodan kao prašak ili vodena otopina.
The method according to claim 7, wherein the at least one of the chemical substance and the preparation is a phytosanitary active substance, a fertilizer or a phytofortifier. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 5 do 7, pri čemu je kemijska tvar i/ili pripravak fitosanitarno aktivna tvar, gnojivo i/ili sredstvo za ojačavanje bilja.